Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: Negative prognostic impact and therapeutic relevance

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 161-169

  Lan, Jui ^a   Tai, Hui Chun ^b   Lee, Sung Wei ^c   Chen, Tzu Ju ^c   Huang, Hsuan Ying ^a   Li, Chien Feng ^c,d,e,f,g  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Arginine deprivation; ASS1; Nasopharyngeal carcinoma; Prognosis; Transcriptome

Indexed keywords

ARGININE; ARGININOSUCCINATE SYNTHASE; CISPLATIN; TRANSCRIPTOME;

ADULT; AMINO ACID METABOLISM; ARTICLE; BIOSYNTHESIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NASOPHARYNX CARCINOMA; NECK LYMPH NODE METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PYROSEQUENCING; SQUAMOUS CELL CARCINOMA; STRATIFICATION; TISSUE SECTION; TRANSCRIPTOMICS;

ADULT; AGED; AMINO ACIDS; ARGININOSUCCINATE SYNTHASE; BIOSYNTHETIC PATHWAYS; CLUSTER ANALYSIS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 84893813110     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1020-8     Document Type: Article

References (32)

1. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:421-9.
2. Chan JPB, Kuo TT, et al. Nasopharyngeal carcinoma World Health Organization classification of tumors - pathology and genetics: head and neck tumors. Lyon: IARC Press; 2005. p. 85-97.
3. Fang FM, Chien CY, Tsai WL, Chen HC, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. Intensity-modulated radiotherapy - a longitudinal study. Int J Radiat Oncol Biol Phys. 2008;72:356-64.
4. Fang FM, Tsai WL, Chen HC, Hsu HC, et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: Comparisons of four radiotherapy techniques. Cancer. 2007;109:313-21.
5. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008;20:264-9.
6. Tham IW, Lu JJ. Controversies and challenges in the current management of nasopharyngeal cancer. Expert Rev Anticancer Ther. 2010;10:1439-50.
7. Lin JC, Jan JS, Hsu CY, Liang WM, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631-7.
8. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5:423-8.
9. Wee J, Tan EH, Tai BC, Wong HB, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730-8.
10. Hui AB, Or YY, Takano H, Tsang RK, et al. Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res. 2005;65:8125-33.
11. Hwang CF, Huang HY, Chen CH, Chien CY, et al. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth. Int J Radiat Oncol Biol Phys. 2011;82:597-604.
12. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:451-62.
13. Tai HC, Huang HY, Lee SW, Lin CY, et al. Associations of Rsf-1 overexpression with poor therapeutic response and worse survival in patients with nasopharyngeal carcinoma. J Clin Pathol. 2012;65:248-53.
14. Snijders AM, Nowak N, Segraves R, Blackwood S, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet. 2001;29:263-4.
15. Liu X, Wang X, Zhang J, Lam EK, et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene. 2010;29:442-50.
16. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10:267-77.
17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
18. Smerc A, Sodja E, Legisa M. Posttranslational modification of 6-phosphofructo-1-kinase as an important feature of cancer metabolism. PLoS One. 2011;6:e19645.
19. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85-95.
20. Sengupta S, den Boon JA, Chen IH, Newton MA, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006;66:7999-8006.
21. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, et al. Argininosuccinate synthetase from the urea cycle to the citrulline-no cycle. European J Biochemistr/FEBS. 2003;270:1887-99.
22. Dillon BJ, Prieto VG, Curley SA, Ensor CM, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: A method for identifying cancers sensitive to arginine deprivation. Cancer. 2004;100:826-33.
23. Wheatley DN. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin Cancer Biol. 2005;15:247-53.
24. Delage B, Fennell DA, Nicholson L, McNeish I, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer J Int du cancer. 2010;126:2762-72.
25. Yang TS, Lu SN, Chao Y, Sheen IS, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer. 2010;103:954-60.
26. Edge SB, Byrd David R., Compton, Carolyn C., Fritz, April G. American Joint Committee on Cancer: AJCC cancer staging manual. (7th ed.). New York, NY, Springer-Verlag, 2010.
27. Huang HY, Wu WR, Wang YH, Wang JW, et al. Ass1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clinical Cancer Res: Off J Am Assoc Cancer Res. 2013;19:2861-72.
28. Fang FM, Chien CY, Li CF, Shiu WY, et al. Effect of S-phase kinase-associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2009;73:202-7.
29. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. International J Cancer J Int du Cancer. 2009;125:1454-63.
30. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clinical Cancer Res: Off J Am Assoc Cancer Res. 2006;12:7126-31.
31. Kobayashi E, Masuda M, Nakayama R, Ichikawa H, et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther. 2010;9:535-44.
32. Tsai WB, Aiba I, Lee SY, Feun L, et al. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther. 2009;8:3223-33.